Navigation Links
For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
Date:6/5/2013

BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists' treatment decisions for second- and subsequent-line metastatic castrate-resistant prostate cancer (mCRPC), and that improved symptom control and quality of life is one of the greatest unmet needs in this indication. Interviewed thought leaders expressed optimism that cabozantinib (Exelixis's Cometriq) and radium-223 (Algeta/Bayer HealthCare's Xofigo) will have an advantage over sales-leading abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga) on this attribute and will help to partially fulfill the large unmet need.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Prostate Cancer (Second- and Subsequent-Line Metastatic Castrate-Resistant): What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Have to Offer in Order to Gain Traction in This Crowded and Competitive Market finds that surveyed U.S. managed care organization pharmacy directors are most willing to grant favorable formulary status to new second- and subsequent-line mCRPC therapies offering  increased median overall survival (MOS) over currently available treatment options. Nevertheless, nearly half of the surveyed payers indicated that they would not reimburse a new therapy priced the same as enzalutamide (Medivation/Astellas Pharma's Xtandi) or higher that offered a three-month improvement in median overall survival over enzalutamide, most commonly stating insufficient clinical benefit to grant reimbursement.     

The report also finds that surveyed U.S. oncologists would prescribe the emerging hormonal agent orteronel (Takeda/Millennium) to 25 percent of their second- and subsequent-line mCRPC patients - however, Decision Resources forecasts that orteronel will earn a more conservative patient share owing primarily to its late launch compared with its main competitors - abiraterone and enzalutamide - in the United States.

"Early-stage clinical data for orteronel are encouraging," said Decision Resources Senior Business Insight Analyst Dr. Karen Pomeranz . "Thought leaders are enthusiastic about hormonal therapies, in particular CYP17 inhibitors and state that they offer high efficacy and a more manageable safety and tolerability profile compared with that associated with standard chemotherapy. However, by the time orteronel will reach the market, the current hormonal therapies, abiraterone and enzalutamide, will have become well entrenched in the treatment algorithm for second- and subsequent-line mCRPC."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
2. Hospira to Host Conference Call for Second-quarter 2012 Results
3. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
4. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
5. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
6. Hospira Reports Second-Quarter 2012 Results
7. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
8. WuXi PharmaTech Announces Second-Quarter 2012 Results
9. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):